Patents by Inventor Francis Kappler

Francis Kappler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8431527
    Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: April 30, 2013
    Assignee: Fox Chase Cancer Center
    Inventors: Truman R. Brown, Francis Kappler
  • Publication number: 20110112188
    Abstract: The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Application
    Filed: September 9, 2010
    Publication date: May 12, 2011
    Inventors: ANNETTE TOBIA, FRANCIS KAPPLER
  • Publication number: 20110034522
    Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.
    Type: Application
    Filed: October 25, 2010
    Publication date: February 10, 2011
    Inventors: Truman R. Brown, Francis Kappler
  • Publication number: 20100310482
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Application
    Filed: June 3, 2010
    Publication date: December 9, 2010
    Applicant: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20100297046
    Abstract: The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Application
    Filed: March 30, 2007
    Publication date: November 25, 2010
    Applicant: DYNAMIS THERAPEUTICS, INC.
    Inventors: Michael Schwartz, Francis Kappler, Bangying Su
  • Patent number: 7749503
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: July 6, 2010
    Assignee: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Patent number: 7671019
    Abstract: The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, an enzyme that mediates 3DG synthesis, is also present in the skin. Thus, the invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: March 2, 2010
    Assignee: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Patent number: 7622117
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: November 24, 2009
    Assignee: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20080292568
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Application
    Filed: June 15, 2007
    Publication date: November 27, 2008
    Applicant: Dynamis Therapeutics, Inc.
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20070270335
    Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.
    Type: Application
    Filed: August 6, 2007
    Publication date: November 22, 2007
    Inventors: Truman Brown, Francis Kappler
  • Publication number: 20070065443
    Abstract: The invention relates to the discovery that levels of collagen and elastin can be modulated by changing the flux through the Amadori Pathway and that copper containing compounds and complexes inhibit the enzyme fructoseamine-3-kinase.
    Type: Application
    Filed: August 4, 2006
    Publication date: March 22, 2007
    Inventors: Annette Tobia, Francis Kappler, Michael Schwartz
  • Publication number: 20070021357
    Abstract: The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Application
    Filed: June 16, 2006
    Publication date: January 25, 2007
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20060247155
    Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.
    Type: Application
    Filed: June 29, 2006
    Publication date: November 2, 2006
    Inventors: Truman Brown, Francis Kappler
  • Patent number: 7071298
    Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to treat glycogen storage diseases, including Fanconi's syndrome, as well as other pathological conditions resulting from the formation of AGE-proteins.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: July 4, 2006
    Assignee: Fox Chase Cancer Center
    Inventors: Truman R. Brown, Francis Kappler
  • Publication number: 20060110439
    Abstract: The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component.
    Type: Application
    Filed: October 21, 2005
    Publication date: May 25, 2006
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20060089316
    Abstract: Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.
    Type: Application
    Filed: October 25, 2004
    Publication date: April 27, 2006
    Inventors: Truman Brown, Francis Kappler, Steven Seeholzer
  • Publication number: 20050159383
    Abstract: The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, an enzyme that mediates 3DG synthesis, is also present in the skin. Thus, the invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.
    Type: Application
    Filed: October 15, 2004
    Publication date: July 21, 2005
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20030219440
    Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
    Type: Application
    Filed: July 18, 2002
    Publication date: November 27, 2003
    Inventors: Annette Tobia, Francis Kappler
  • Publication number: 20020111291
    Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications and the effects of glycogen storage diseases, including Fanconi's syndrome.
    Type: Application
    Filed: October 10, 2001
    Publication date: August 15, 2002
    Inventors: Truman R. Brown, Francis Kappler
  • Patent number: 6004958
    Abstract: The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: December 21, 1999
    Assignee: Fox Chase Cancer Center
    Inventors: Truman R. Brown, Francis Kappler, Benjamin Szwergold, Sundeep Lal, Bangying Su